Expertise in
4
conditions

Dr. Rodney M. Jamil

Hematology
Riverview Medical Center
1 Riverview Plaza, 
Red Bank, NJ 
Expertise in
4
conditions
Riverview Medical Center
1 Riverview Plaza, 
Red Bank, NJ 

Overview

Rodney Jamil is a Hematologist practicing medicine in Red Bank, New Jersey.

Dr. Jamil is highly rated in 4 conditions, according to our data. His clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer, Thrombocytopenia, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Schnitzler Syndrome.

Dr. Jamil is board certified in Medical Oncology and American Board Of Internal Medicine . He is actively involved in clinical research, participating in 6 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in MA

Board Certifications

Medical Oncology
American Board Of Internal Medicine

Fellowships

Beth Israel Deaconess Medical Center-Main Campus

Hospital Affiliations

Penn Highlands Mon Valley
Penn Highlands Connellsville

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Riverview Medical Center
1 Riverview Plaza, Red Bank, NJ 7701.

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
View 5 Less Clinical Trials
Similar Doctors
Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required
Before you request

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
 (5.2 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Schuster is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Schuster is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Schuster is board certified in Hematology, 1986, Internal Medicine, 1984, and Medical Oncology, 1989. Dr. Schuster is currently accepting new patients.

Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required
Before you request

Abramson Cancer Center Perelman 4th Floor West

3400 Civic Center Boulevard, West Pavilion, 4th Floor, 
Philadelphia, PA 
 (5.2 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stefan Barta is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Barta is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, T-Cell Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Barta is board certified in Medical Oncology, 2010 and Hematology, 2010. Dr. Barta is currently accepting new patients.

Expertise in
28
conditions
Dr. Adam Cuker
Hematology
Expertise in
28
conditions
Dr. Adam Cuker
Hematology
Referral may be required
Before you request

Penn Blood Disorders Center

3400 Civic Center Boulevard, South Pavilion, 1st Floor, 
Philadelphia, PA 
 (5.2 miles away)
215-615-6555
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Adam Cuker is a Hematologist practicing medicine in Philadelphia, Pennsylvania. Dr. Cuker is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, Splenectomy, and Knee Replacement. Dr. Cuker is board certified in Hematology, 2009. Dr. Cuker is currently accepting new patients.

Frequently Asked Questions about Dr. Rodney M. Jamil

Is Dr. Rodney M. Jamil a top-rated expert for ALK-Positive Non-Small Cell Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rodney M. Jamil is classified as an Advanced expert for ALK-Positive Non-Small Cell Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rodney M. Jamil specialize in?

While Dr. Rodney M. Jamil is a Hematology, they have specific expertise in ALK-Positive Non-Small Cell Lung Cancer, Thrombocytopenia, and Monoclonal Gammopathy of Undetermined Significance (MGUS). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rodney M. Jamil accept my insurance?

Dr. Rodney M. Jamil accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jamil's expertise for a condition
ConditionClose
      View All 53 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile